Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP4 | P49662 | 1/20 | 0.36 |
| ▸ | CASP5 | P51878 | 1/20 | 0.36 |
| ▸ | CASP9 | P55211 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.36 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24095937 | 0.82 | CTSK (0.49) | EPHX1ACHECTSK | |
| SCHEMBL24096191 | 0.82 | CTSK (0.49) | EPHX1ACHECTSK | |
| SCHEMBL24095704 | 0.81 | EPHX1 (0.43) | EPHX1ACHECTSK | |
| SCHEMBL24096325 | 0.81 | FAAH (0.45) | — | |
| SCHEMBL26294539 | 0.80 | EPHX1 (0.41) | EPHX1ACHECTSK | |
| SCHEMBL24096030 | 0.79 | EPHX1 (0.48) | EPHX1 | |
| SCHEMBL31521489 | 0.75 | NPC1 (0.40) | EPHX1CASP3ACHE | |
| SCHEMBL7771224 | 0.75 | EPHX1 (0.50) | EPHX1ACHE | |
| SCHEMBL7771229 | 0.75 | EPHX1 (0.50) | EPHX1ACHE | |
| SCHEMBL24096347 | 0.74 | EPHX1 (0.53) | EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | EPHX1 3564/4885CASP3 2201/4885ACHE 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.